EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private
EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns. The post EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private appeared first on GEN - Genetic Engineering and Biotechnology News .
Swedish private equity firm EQT has announced its intention to acquire the life sciences tools, diagnostics, and workflow solutions provider Qiagen for a deal valued at approximately $12.1 billion. The acquisition would take Qiagen private, following a series of failed takeover attempts over nearly a decade. EQT Private Equity, a holding company managed by affiliates of EQT, will finance the transaction.
The offer follows Qiagen's strategic review, which concluded that a buyout by EQT would provide the company with the greatest long-term growth potential. EQT's Chairman, Stephen H. Rusckowski, emphasized that this acquisition offers shareholders compelling value while positioning Qiagen for its next phase of development under private ownership.
The premium paid by EQT for Qiagen exceeds its stock price at the time of the offer, with a 40.3% premium compared to the last trading day before the acquisition news.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
